ANI PHARMACEUTICALS, INC Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
ANI PHARMACEUTICALS, INC (ANIP) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of -$2.97 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-27
- ANI PHARMACEUTICALS, INC valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2024-12-31 was $1.50M.
- ANI PHARMACEUTICALS, INC valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2014-12-31 was $16.70M.
- ANI PHARMACEUTICALS, INC valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was -$2.97M.
- ANI PHARMACEUTICALS, INC valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was -$1.49M, a 18700.00% decline from fiscal 2023.
- ANI PHARMACEUTICALS, INC valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $8.00K, a 100.00% increase from fiscal 2022.
- ANI PHARMACEUTICALS, INC valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $4.00K.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 3 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|---|
| 2025-12-31 | -$2.97M 10-K · filed 2026-02-27 | ||
| 2024-12-31 | $1.50M 10-K · filed 2025-02-28 | -$1.49M 10-K · filed 2026-02-27 | |
| 2023-12-31 | $8.00K 10-K · filed 2026-02-27 | ||
| 2022-12-31 | $4.00K 10-K · filed 2025-02-28 | ||
| 2021-12-31 | -$187.00K 10-K · filed 2024-02-29 | ||
| 2020-12-31 | $169.00K 10-K · filed 2023-03-09 | ||
| 2019-12-31 | $1.83M 10-K · filed 2022-03-15 | ||
| 2018-12-31 | -$221.00K 10-K · filed 2021-03-11 | ||
| 2017-12-31 | -$51.00K 10-K · filed 2020-02-27 | ||
| 2016-12-31 | -$134.00K 10-K · filed 2019-02-27 | ||
| 2015-12-31 | $0.00 10-K · filed 2018-02-27 | ||
| 2014-12-31 | $16.70M 10-K · filed 2016-02-23 | $16.73M 10-K · filed 2017-03-02 | |
| 2013-12-31 | $414.00K 10-K · filed 2016-02-23 | -$414.00K 10-K · filed 2014-02-28 | |
| 2012-12-31 | $1.52M 10-K · filed 2014-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |